Clinical Trials Browser

Phase 1 × Lymphoma, B-Cell × 30 days × Clear all

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1 Recruiting

224 enrolled

Lymphoid

Lymphoma, B-Cell

NCT07532525 2026-04-16

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Phase 1 Not yet recruiting

12 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT06544265 2026-04-14

SynKIR-310 for Relapsed/Refractory B-NHL

Phase 1 Recruiting

36 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Dendritic Cell Sarcoma, Interdigitating

NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

24 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

127 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT05272384 2026-04-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Phase 1 Recruiting

32 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05627245 2026-04-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1 Active not recruiting

48 enrolled

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05784441 2026-04-13

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Phase 1 Active not recruiting

21 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT01087294 2026-04-08

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Phase 1 Completed

85 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT04488354 2026-04-08

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Phase 1 Completed

16 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06824701 2026-04-06